» Articles » PMID: 27548148

Trichostatin A Enhances the Apoptotic Potential of Palladium Nanoparticles in Human Cervical Cancer Cells

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2016 Aug 23
PMID 27548148
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Cervical cancer ranks seventh overall among all types of cancer in women. Although several treatments, including radiation, surgery and chemotherapy, are available to eradicate or reduce the size of cancer, many cancers eventually relapse. Thus, it is essential to identify possible alternative therapeutic approaches for cancer. We sought to identify alternative and effective therapeutic approaches, by first synthesizing palladium nanoparticles (PdNPs), using a novel biomolecule called saponin. The synthesized PdNPs were characterized by several analytical techniques. They were significantly spherical in shape, with an average size of 5 nm. Recently, PdNPs gained much interest in various therapies of cancer cells. Similarly, histone deacetylase inhibitors are known to play a vital role in anti-proliferative activity, gene expression, cell cycle arrest, differentiation and apoptosis in various cancer cells. Therefore, we selected trichostatin A (TSA) and PdNPs and studied their combined effect on apoptosis in cervical cancer cells. Cells treated with either TSA or PdNPs showed a dose-dependent effect on cell viability. The combinatorial effect, tested with 50 nM TSA and 50 nMPdNPs, had a more dramatic inhibitory effect on cell viability, than either TSA or PdNPs alone. The combination of TSA and PdNPs had a more pronounced effect on cytotoxicity, oxidative stress, mitochondrial membrane potential (MMP), caspase-3/9 activity and expression of pro- and anti-apoptotic genes. Our data show a strong synergistic interaction between TSA and PdNPs in cervical cancer cells. The combinatorial treatment increased the therapeutic potential and demonstrated relevant targeted therapy for cervical cancer. Furthermore, we provide the first evidence for the combinatory effect and cytotoxicity mechanism of TSA and PdNPs in cervical cancer cells.

Citing Articles

Cancer epigenetics: from laboratory studies and clinical trials to precision medicine.

Yu X, Zhao H, Wang R, Chen Y, Ouyang X, Li W Cell Death Discov. 2024; 10(1):28.

PMID: 38225241 PMC: 10789753. DOI: 10.1038/s41420-024-01803-z.


The Emerging Role of Histone Deacetylase Inhibitors in Cervical Cancer Therapy.

Psilopatis I, Garmpis N, Garmpi A, Vrettou K, Sarantis P, Koustas E Cancers (Basel). 2023; 15(8).

PMID: 37190151 PMC: 10137219. DOI: 10.3390/cancers15082222.


Inorganic Nanomaterials Used in Anti-Cancer Therapies:Further Developments.

Dlugosz O, Matyjasik W, Hodacka G, Szostak K, Matysik J, Krawczyk P Nanomaterials (Basel). 2023; 13(6).

PMID: 36986024 PMC: 10051539. DOI: 10.3390/nano13061130.


Pharmacological Properties of Trichostatin A, Focusing on the Anticancer Potential: A Comprehensive Review.

Bouyahya A, El Omari N, Bakha M, Aanniz T, El Menyiy N, El Hachlafi N Pharmaceuticals (Basel). 2022; 15(10).

PMID: 36297347 PMC: 9612318. DOI: 10.3390/ph15101235.


Emerging concepts in designing next-generation multifunctional nanomedicine for cancer treatment.

Chakraborty K, Tripathi A, Mishra S, Mallick A, Sinha Roy R Biosci Rep. 2022; 42(7).

PMID: 35638450 PMC: 9272595. DOI: 10.1042/BSR20212051.


References
1.
Liu J, Wang Z . Increased Oxidative Stress as a Selective Anticancer Therapy. Oxid Med Cell Longev. 2015; 2015:294303. PMC: 4529973. DOI: 10.1155/2015/294303. View

2.
Adjei A . Ras signaling pathway proteins as therapeutic targets. Curr Pharm Des. 2001; 7(16):1581-94. DOI: 10.2174/1381612013397258. View

3.
Fulda S . Modulation of TRAIL-induced apoptosis by HDAC inhibitors. Curr Cancer Drug Targets. 2008; 8(2):132-40. DOI: 10.2174/156800908783769355. View

4.
de la Vega L, Grishina I, Moreno R, Kruger M, Braun T, Schmitz M . A redox-regulated SUMO/acetylation switch of HIPK2 controls the survival threshold to oxidative stress. Mol Cell. 2012; 46(4):472-83. DOI: 10.1016/j.molcel.2012.03.003. View

5.
Oberley T, Oberley L . Antioxidant enzyme levels in cancer. Histol Histopathol. 1997; 12(2):525-35. View